Login to Your Account

Analysts: 'High Risk, High Reward'

Targanta Revives Oritavancin: Next Weapon Against cSSSI?

By Randall Osborne

Monday, November 26, 2007
Remember FDA-stalled oritavancin? The hospital-based glycopeptide antibiotic acquired in 2001 by InterMune Inc. from Eli Lilly and Co. (which developed the compound as a replacement for vancomycin, which still takes an estimated 80 percent share of the market) was bought by Targanta Therapeutics Inc around Christmas four years later. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription